Business Context and Reporting Period
This Form 8-K Current Report was filed by Relmada Therapeutics, Inc. on July 16, 2015, covering events that occurred on July 14, 2015. The filing primarily addresses corporate governance changes, specifically the appointment of new directors and the formation of board committees.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial details disclosed relate to director compensation:
- Director Cash Compensation: $30,000 per year for Charles J. Casamento, payable in quarterly installments.
- Equity Grant: 128,825 stock options granted to Mr. Casamento with a 10-year term.
- Exercise Price: Equal to the share price on July 14, 2015.
- Vesting Schedule: 25% vests on the first anniversary; the remaining 75% vests in equal quarterly increments over the subsequent three years.
Material Changes
The following material changes to the Board of Directors and governance structure were reported:
- Appointment of Director: Charles J. Casamento was appointed as a director and designated as the Chair of the newly formed Audit Committee.
- Change in Leadership: Sandesh Seth was appointed as Chairman of the Board (previously Lead Director since January 2014).
- Committee Formation: The Board established an Audit Committee and a Compensation Committee.
- Committee Membership:
- Audit Committee: Charles J. Casamento (Chair), Shreeram Agharkar, Nabil Yazgi.
- Compensation Committee: Shreeram Agharkar (Chair), Nabil Yazgi, Sandesh Seth (Advisor).
Outlook, Risks, and Management Commentary
The filing contains no forward-looking guidance, financial outlook, or discussion of risks and contingencies. Management commentary is limited to the background of the new director, Charles J. Casamento, highlighting his extensive experience in biotechnology M&A, having taken four companies public and completed over 100 major business development deals. The filing notes that Mr. Casamento's appointment is subject to shareholder ratification at the 2015 annual meeting.
Investor Verification Checklist
- Verify the ratification of Charles J. Casamento as a director at the 2015 annual shareholders meeting.
- Review the full text of the Director Agreement (Exhibit 10.1) and Indemnity Agreement (Exhibit 10.2) for additional terms not summarized in the filing.
- Confirm the exact exercise price of the 128,825 options granted to Mr. Casamento based on the closing share price on July 14, 2015.
- Monitor future filings for the formal election results of the new board structure.